Immuxell Biotech

ImmuXell Biotech was founded in January 2021, with a registered capital of 20 million yuan, located in the Kangqiao Industrial Zone of Shanghai's Zhangjiang Science City. It is a clinical-stage biopharmaceutical technology innovation enterprise focused on the research and development and production of breakthrough immunotherapy drugs. Its main product is a novel immune cell preparation targeting solid tumors. Since its establishment, ImmuXell Biotech has experienced rapid development in platform construction, pipeline building, and product layout. The future goal is to identify shared gene mutations and tumor neoantigens, and to develop a series of TCR products for treating recurrent and refractory malignant tumors such as pancreatic cancer. The aim is to combine personalization and universality in cell therapy products, improving the effectiveness and accessibility of cell therapies, benefiting a wider patient population.